Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.87%
#3 Cysic Cysic +15.83%
#4 Fabric Protocol Fabric Protocol +12.01%
#5 Bedrock Bedrock +9.08%
#6 Cap Cap +8.32%
#7 stake.link stake.link +6.45%
#8 Pons Pons +5.85%
#9 Enso Enso +5.58%
#10 DUSK Network DUSK Network +4.98%
Coin of the day
EXOD EXOD
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Pozycja w akcjach #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Cena akcji
$0.1
Ostatnia synchronizacja: 2024-06-18
Kapitalizacja rynkowa
$1.31M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Pascal Biosciences Inc. (PSCBF)

Kategoria

Healthcare
Przychody dla Pascal Biosciences Inc. (PSCBF)
Przychody w Feb 2024 TTM: $700.83K
Według najnowszych raportów finansowych Pascal Biosciences Inc., obecny przychód firmy (TTM) wynosi $700.83K. W roku 2022 firma osiągnęła przychód w wysokości 0.00 równa się przychodu z roku 2021, który wynosił 0.00. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Pascal Biosciences Inc. od 2019 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $700.83K 41.81%
2023 $494.20K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,801,231.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 859,063.16%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 1,442,584.10%
BE